GW Pharmaceuticals’ cannabis drug gets FDA orphan drug status
The orphan drug status to the drug, Epidiolex, entitles GW Pharmaceuticals to a seven-year exclusive market period. TSC is the third orphan indication that the company is targeting
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.